The Global Drug sales of Humira stood at USD 21,661.65 Millions in 2022
The indicator recorded a historical growth (CAGR) of3.15% between 2019 to 2022 and is expected to decline by ...
GlobalData projects the indicator to decline at a CAGR of...
Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). Humira consists of heavy and light chain variable regions and human IgG1 k constant regions. Adalimumab is produced by recombinant DNA technology in chinese hamster ovary cells expression system. It is formulated as injection for subcutaneous route of administration.
Mechanism of Action
Humira (adalimumab) is a fully human anti-TNF-alpha monoclonal antibody that neutralizes the activity of tumor necrosis factor alpha (TNF-alpha), a type of cytokine that plays a central role in inflammatory reactions in patients with autoimmune diseases. Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Tumor necrosis factor-alpha is one of the most important cytokines. It plays a critical role in the cascade of inflammatory reactions. Adalimumab modulates the biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration. Adalimumab has efficacy to inhibit the tumor necrosis factor indications like rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis and plaque psoriasis.
Humira Overview
Humira is marketed for the treatment of several indications including Pyoderma Gangrenosum, Axial Spondyloarthritis, Hidradenitis Suppurativa, Uveitis, Ankylosing Spondylitis (Bekhterev's Disease), Psoriatic Arthritis, Psoriasis, Ulcerative Colitis, Rheumatoid Arthritis, Crohn's Disease (Regional Enteritis), Anterior Uveitis, Behcet Disease, Intermediate Uveitis, Plaque Psoriasis (Psoriasis Vulgaris), Polyarticular Juvenile Idiopathic Arthritis (PJIA), and Posterior Uveitis. The indications belong to several therapy areas including Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Immunology, Musculoskeletal Disorders, and Ophthalmology.
Humira was first approved in 2015 and is sold globally including the US, the UK, France, Germany, and Japan by several pharma giants including AbbVie Inc, Eisai Co Ltd, and Abbott Laboratories. Humira drug sales recorded a single digit Year on Year growth in 2022. Humira drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward